Dan O'Day (AP Images)

September 12, 2020 06:16 PM EDTUpdated September 14, 09:46 AM

Gilead CEO Dan O'Day's $21B M&A deal to buy Immunomedics gets some harsh reviews

John Carroll

Editor & Founder

After a wild, 4-year roller coaster ride, ImmunoMedics $IMMU is getting its fairy-tale ending after all.

Sunday evening Gilead $GILD put the weekend rumors to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Bristol Myers bets $1.5B on BioNTech's PD-L1xVEGF from Biotheus

Sanofi to snap up Blueprint Medicines and mastocytosis drug Ayvakit for $9.1B

Kymera unveils ‘exceptional’ Phase 1 data for its Dupixent-in-a-pill program

Vera posts positive Phase 3 rare kidney disease data, but crowded market looms

In race with Merus, Bicara makes the case for two-year survival data

sponsored

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...